{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:11:50Z","timestamp":1781737910159,"version":"3.54.5"},"reference-count":151,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiresorptive treatments for postmenopausal osteoporosis have been studied extensively, but due to the volume of published data and lack of head-to-head trials, it is difficult to evaluate and compare their fracture reduction efficacy. The objective of this review is to summarize the results from clinical trials that have fracture as an endpoint and to discuss the factors in study design and populations that can affect the interpretation of the results. Although there are numerous observational studies suggesting that estrogen and hormone replacement therapies may reduce the risk of vertebral and nonvertebral fractures, there is no large, prospective, randomized, placebo-controlled, double-blind clinical trial demonstrating fracture efficacy. The effects of raloxifene, alendronate, risedronate, and salmon calcitonin on increasing bone mineral density (BMD) and decreasing fracture risk have been shown in randomized, placebo-controlled, double-blind clinical trials of postmenopausal women with osteoporosis. Although the increases in lumbar spine BMD vary greatly in these trials, the decrease in relative risk of vertebral fractures is similar among therapies. However, nonvertebral fracture efficacy has not been consistently demonstrated. Combined administration of two antiresorptive therapies results in greater BMD increases, but the effects on fracture risk are unknown. Direct comparisons of clinical trial results should be considered carefully, given the differences in study design and populations. Differences in study design that may influence the efficacy of fracture risk reduction include calcium and vitamin D supplementation, primary fracture endpoints, definition of vertebral deformity or fracture, discontinuation rates, and statistical power. Factors in the study population that may influence fracture efficacy include the age of the population and the proportion of subjects with prevalent fractures. The use of surrogate endpoints such as BMD to predict fracture risk should be approached with caution, as the relationship between BMD changes and fracture risk reduction with antiresorptive therapies is uncertain. Consideration of these results from clinical trials can contribute to clinical judgment in selecting the best treatment option for postmenopausal osteoporosis.<\/jats:p>","DOI":"10.1210\/edrv.23.1.0453","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T18:26:14Z","timestamp":1389205574000},"page":"16-37","source":"Crossref","is-referenced-by-count":131,"title":["Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint"],"prefix":"10.1210","volume":"23","author":[{"given":"Robert","family":"Marcus","sequence":"first","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, and the Musculoskeletal Research Laboratory, Geriatric Research, Education, and Clinical Center, Veterans\u2019 Affairs Medical Center (R.M.), Palo Alto, California 94304"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayme","family":"Wong","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company (M.W., H.H.III, J.L.S.), Indianapolis, Indiana 46285"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Hunter","family":"Heath","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company (M.W., H.H.III, J.L.S.), Indianapolis, Indiana 46285"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Stock","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company (M.W., H.H.III, J.L.S.), Indianapolis, Indiana 46285"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"2020071612100243900_R1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198606263142605","article-title":"Involutional osteoporosis.","volume":"314","author":"Riggs","year":"1986","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJM199208273270908","article-title":"The prevention and treatment of osteoporosis.","volume":"327","author":"Riggs","year":"1992","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R3","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1001\/jama.1941.02820220007002","article-title":"Postmenopausal osteoporosis.","volume":"116","author":"Albright","year":"1941","journal-title":"JAMA"},{"key":"2020071612100243900_R4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0149-2918(99)80022-8","article-title":"Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.","volume":"21","author":"Meunier","year":"1999","journal-title":"Clin Ther"},{"key":"2020071612100243900_R5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis.","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1094-6950(06)60409-5","article-title":"A review of clinical trials of therapies for osteoporosis using fracture as an end point.","volume":"2","author":"Blank","year":"1999","journal-title":"J Clin Densitom"},{"key":"2020071612100243900_R7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jama.1994.03520170077040","article-title":"Users\u2019 guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group.","volume":"272","author":"Oxman","year":"1994","journal-title":"JAMA"},{"key":"2020071612100243900_R8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/Progestin Replacement Study (HERS) Research Group.","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"2020071612100243900_R9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s001980070037","article-title":"Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men.","volume":"11","author":"Melton","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-128-10-199805150-00001","article-title":"The association of radiographically detected vertebral fractures with back pain and function: a prospective study.","volume":"128","author":"Nevitt","year":"1998","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/jbmr.5650070413","article-title":"Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group.","volume":"7","author":"Ettinger","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/archinte.159.11.1215","article-title":"Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group.","volume":"159","author":"Kado","year":"1999","journal-title":"Arch Intern Med"},{"key":"2020071612100243900_R13","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.1996.00440200087011","article-title":"Vertebral fracture and other predictors of physical impairment and health care utilization.","volume":"156","author":"Huang","year":"1996","journal-title":"Arch Intern Med"},{"key":"2020071612100243900_R14","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1359\/jbmr.2000.15.8.1564","article-title":"Consequences of vertebral deformities in older men and women.","volume":"15","author":"Pluijm","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R15","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","article-title":"Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures.","volume":"15","author":"Oleksik","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","article-title":"Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group.","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1532-5415.2000.tb02641.x","article-title":"Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass.","volume":"48","author":"Ensrud","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"2020071612100243900_R18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1359\/jbmr.1999.14.1.90","article-title":"Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group.","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/BF03343614","article-title":"The burden of osteoporosis.","volume":"22","author":"Kanis","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"2020071612100243900_R20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/8756-3282(95)00258-4","article-title":"The worldwide problem of osteoporosis: insights afforded by epidemiology.","volume":"17","author":"Riggs","year":"1995","journal-title":"Bone"},{"key":"2020071612100243900_R21","author":"Delmas","year":"1999"},{"key":"2020071612100243900_R22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-114-11-919","article-title":"Pre-existing fractures and bone mass predict vertebral fracture incidence in women.","volume":"114","author":"Ross","year":"1991","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/jbmr.5650081010","article-title":"Long-term fracture prediction by bone mineral assessed at different skeletal sites.","volume":"8","author":"Melton III","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s001980050224","article-title":"Interim report and recommendations of the World Health Organization Task-Force for osteoporosis.","volume":"10","author":"Genant","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R25","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.","volume":"312","author":"Marshall","year":"1996","journal-title":"Br Med J"},{"key":"2020071612100243900_R26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0002-9343(97)90029-2","article-title":"Osteoporosis: trials and tribulations.","volume":"103","author":"Seeman","year":"1997","journal-title":"Am J Med"},{"key":"2020071612100243900_R27","first-page":"S102","article-title":"Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs","volume":"11","author":"Cummings","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R28","author":"Black","year":"1999"},{"key":"2020071612100243900_R29","first-page":"S198","article-title":"Relationships between changes in bone mineral density and the risk of new vertebral fractures with raloxifene treatment","volume":"11","author":"Sarkar","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R30","author":"Cummings","year":"1999"},{"key":"2020071612100243900_R31","first-page":"S137","article-title":"Predicting the effect of antiresorptive treatments on risk of vertebral fractures: a meta-analysis","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R32","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2020071612100243900_R33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density.","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612100243900_R34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1385\/JCD:2:3:323","article-title":"Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel.","volume":"2","author":"Miller","year":"1999","journal-title":"J Clin Densitom"},{"key":"2020071612100243900_R35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001980070088","article-title":"Clinical use of biochemical markers of bone remodeling: current status and future directions.","volume":"11","author":"Looker","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R36","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1001\/jama.280.24.2119","article-title":"Bone mass, bone fragility, and the decision to treat.","volume":"280","author":"Heaney","year":"1998","journal-title":"JAMA"},{"key":"2020071612100243900_R37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0002-8703(98)70116-4","article-title":"Post hoc subgroup analysis and the truth of a clinical trial.","volume":"136","author":"Adams","year":"1998","journal-title":"Am Heart J"},{"key":"2020071612100243900_R38","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/jbmr.5650111218","article-title":"Correcting calcium nutritional deficiency prevents spine fractures in elderly women.","volume":"11","author":"Recker","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF01623348","article-title":"Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients.","volume":"4","author":"Chevalley","year":"1994","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9343(99)80310-6","article-title":"Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial.","volume":"98","author":"Reid","year":"1995","journal-title":"Am J Med"},{"key":"2020071612100243900_R41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/ajcn\/32.3.540","article-title":"Bone status and fracture rates in two regions of Yugoslavia.","volume":"32","author":"Matkovic","year":"1979","journal-title":"Am J Clin Nutr"},{"key":"2020071612100243900_R42","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(88)90065-7","article-title":"Dietary calcium and risk of hip fracture: 14-year prospective population study.","volume":"2","author":"Holbrook","year":"1988","journal-title":"Lancet"},{"key":"2020071612100243900_R43","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1359\/jbmr.1997.12.9.1321","article-title":"Calcium for prevention of osteoporotic fractures in postmenopausal women.","volume":"12","author":"Cumming","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R44","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","article-title":"Vitamin D3 and calcium to prevent hip fractures in the elderly women.","volume":"327","author":"Chapuy","year":"1992","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.308.6936.1081","article-title":"Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women.","volume":"308","author":"Chapuy","year":"1994","journal-title":"BMJ"},{"key":"2020071612100243900_R46","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","article-title":"Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.","volume":"337","author":"Dawson-Hughes","year":"1997","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-124-4-199602150-00003","article-title":"Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial.","volume":"124","author":"Lips","year":"1996","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00298497","article-title":"Annual injection of vitamin D and fractures of aged bones.","volume":"51","author":"Heikinheimo","year":"1992","journal-title":"Calcif Tissue Int"},{"key":"2020071612100243900_R49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev.publhealth.19.1.55","article-title":"Hormone replacement therapy, heart disease, and other considerations.","volume":"19","author":"Barrett-Connor","year":"1998","journal-title":"Annu Rev Public Health"},{"issue":"Suppl 2","key":"2020071612100243900_R50","first-page":"215","article-title":"The lack of effect of progestogen on bone","volume":"44","author":"Lindsay","year":"1999","journal-title":"J Reprod Med"},{"key":"2020071612100243900_R51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen.","volume":"117","author":"Lufkin","year":"1992","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R52","author":"Nelson","year":"1996"},{"key":"2020071612100243900_R53","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/bmj.310.6977.454","article-title":"Events per person year-a dubious concept.","volume":"310","author":"Windeler","year":"1995","journal-title":"BMJ"},{"key":"2020071612100243900_R54","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(80)92592-1","article-title":"Prevention of spinal osteoporosis in oophorectomised women.","volume":"2","author":"Lindsay","year":"1980","journal-title":"Lancet"},{"key":"2020071612100243900_R55","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures.","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2020071612100243900_R56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women.","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0378-5122(98)00085-1","article-title":"HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial.","volume":"31","author":"Komulainen","year":"1998","journal-title":"Maturitas"},{"key":"2020071612100243900_R58","first-page":"277","article-title":"Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis.","volume":"53","author":"Nachtigall","year":"1979","journal-title":"Obstet Gynecol"},{"key":"2020071612100243900_R59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-122-1-199501010-00002","article-title":"Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group.","volume":"122","author":"Cauley","year":"1995","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0197-2456(97)00078-0","article-title":"Design of the Women\u2019s Health Initiative clinical trial and observational study.","volume":"19","year":"1998","journal-title":"Control Clin Trials"},{"key":"2020071612100243900_R61","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/00003495-199957050-00001","article-title":"Selective estrogen receptor modulators: a look ahead.","volume":"57","author":"Mitlak","year":"1999","journal-title":"Drugs"},{"key":"2020071612100243900_R62","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2020071612100243900_R63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-857X(05)70192-7","article-title":"The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.","volume":"27","author":"Lufkin","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"2020071612100243900_R64","first-page":"S197","article-title":"Raloxifene 60 mg\/day has effects within 12 months in postmenopausal osteoporosis treatment and prevention studies","volume":"43","author":"Maricic","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2020071612100243900_R65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action.","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"2020071612100243900_R66","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/j.1875-9114.1998.tb03899.x","article-title":"The pharmacology and therapeutic utility of bisphosphonates.","volume":"18","author":"Lourwood","year":"1998","journal-title":"Pharmacotherapy"},{"key":"2020071612100243900_R67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/JCD:3:1:079","article-title":"Etidronate therapy in the treatment and prevention of osteoporosis.","volume":"3","author":"Hanley","year":"2000","journal-title":"J Clin Densitom"},{"key":"2020071612100243900_R68","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R69","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2020071612100243900_R69A","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"Looker","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R70","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R71","first-page":"S173","article-title":"The early antifracture efficacy of alendronate in women with osteoporosis: results from FIT","volume":"11","author":"Black","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R72","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612100243900_R73","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","article-title":"Prevention of nonvertebral fractures by alendronate: a meta-analysis. Alendronate Osteoporosis Treatment Study Groups.","volume":"277","author":"Karpf","year":"1997","journal-title":"JAMA"},{"key":"2020071612100243900_R74","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2020071612100243900_R75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/qjmed\/92.3.143","article-title":"Effect of calcitonin on vertebral and other fractures.","volume":"92","author":"Kanis","year":"1999","journal-title":"QJM"},{"key":"2020071612100243900_R77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study.","volume":"109","author":"Chesnut III","year":"2000","journal-title":"Am J Med"},{"key":"2020071612100243900_R78","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0002-9343(00)00539-8","article-title":"What PROOF proves about calcitonin and clinical trials.","volume":"109","author":"Cummings","year":"2000","journal-title":"Am J Med"},{"key":"2020071612100243900_R79","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0140-6736(05)65132-X","article-title":"A tale of two worlds in prescribing etidronate for osteoporosis.","volume":"350","author":"Rosen","year":"1997","journal-title":"Lancet"},{"key":"2020071612100243900_R80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.","volume":"323","author":"Watts","year":"1990","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R81","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","article-title":"Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.","volume":"95","author":"Harris","year":"1993","journal-title":"Am J Med"},{"key":"2020071612100243900_R82","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.","volume":"322","author":"Storm","year":"1990","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R83","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF01623461","article-title":"The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.","volume":"7","author":"Montessori","year":"1997","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R84","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0002-9343(93)90349-T","article-title":"Cyclic etidronate: has the rose lost its bloom?","volume":"95","author":"Marcus","year":"1993","journal-title":"Am J Med"},{"key":"2020071612100243900_R85","first-page":"1","article-title":"Livial: a review of clinical studies.","volume":"106","author":"Moore","year":"1999","journal-title":"Br J Obstet Gynecol"},{"key":"2020071612100243900_R86","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199202063260601","article-title":"Treatment of postmenopausal osteoporosis with calcitriol or calcium.","volume":"326","author":"Tilyard","year":"1992","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R87","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM199202063260609","article-title":"Osteoporosis and its treatment.","volume":"326","author":"Chesnut III","year":"1992","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-113-9-649","article-title":"Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol: a randomized controlled study.","volume":"113","author":"Gallagher","year":"1990","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R89","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.0954-6820.1987.tb01267.x","article-title":"Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol.","volume":"221","author":"Falch","year":"1987","journal-title":"Acta Med Scand"},{"key":"2020071612100243900_R90","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0002-9343(88)90259-8","article-title":"Calcitriol in the treatment of postmenopausal osteoporosis.","volume":"84","author":"Aloia","year":"1988","journal-title":"Am J Med"},{"key":"2020071612100243900_R91","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-110-4-267","article-title":"Calcitriol treatment is not effective in postmenopausal osteoporosis.","volume":"110","author":"Ott","year":"1989","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R92","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/BF00305521","article-title":"Effects of 1\u03b1-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.","volume":"54","author":"Orimo","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"2020071612100243900_R93","first-page":"47","article-title":"Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1\u03b1 (OH)-vitamin D3.","volume":"3","author":"Orimo","year":"1987","journal-title":"Bone Miner"},{"key":"2020071612100243900_R94","first-page":"2223","article-title":"Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence.","volume":"83","author":"Tham","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612100243900_R95","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2105\/AJPH.83.5.694","article-title":"Hip fracture rates in Hong Kong and the United States, 1988 through 1989.","volume":"83","author":"Ho","year":"1993","journal-title":"Am J Public Health"},{"key":"2020071612100243900_R96","first-page":"S198","article-title":"Ipriflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women","volume":"15","author":"Alexandersen","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R97","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00042192-200007040-00003","article-title":"The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society.","volume":"7","year":"2000","journal-title":"Menopause"},{"key":"2020071612100243900_R98","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1385\/JCD:3:2:187","article-title":"Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents.","volume":"3","author":"Wimalawansa","year":"2000","journal-title":"J Clin Densitom"},{"key":"2020071612100243900_R99","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","article-title":"A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.","volume":"104","author":"Wimalawansa","year":"1998","journal-title":"Am J Med"},{"key":"2020071612100243900_R100","first-page":"727","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate\/Estrogen Study Group.","volume":"85","author":"Bone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612100243900_R101","first-page":"3076","article-title":"Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.","volume":"84","author":"Lindsay","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612100243900_R102","first-page":"S157","article-title":"Effects of raloxifene (RLX), alendronate (ALN), and RLX + ALN on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"14","author":"Johnell","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9343(99)80102-8","article-title":"Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study.","volume":"99","author":"Wimalawansa","year":"1995","journal-title":"Am J Med"},{"key":"2020071612100243900_R104","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1385\/JCD:2:3:285","article-title":"Predicting bone loss and fracture risk with biochemical markers: a review.","volume":"2","author":"Ross","year":"1999","journal-title":"J Clin Densitom"},{"key":"2020071612100243900_R105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R106","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.1997.12.1.6","article-title":"Bone microdamage and skeletal fragility in osteoporotic and stress fractures.","volume":"12","author":"Burr","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/152460900318542","article-title":"How long should patients with osteoporosis be treated with bisphosphonates?","volume":"9","author":"Cosman","year":"2000","journal-title":"J Womens Health Gend Based Med"},{"key":"2020071612100243900_R108","first-page":"982","article-title":"Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen\/Progestin Interventions Trial.","volume":"92","author":"Greendale","year":"1998","journal-title":"Obstet Gynecol"},{"key":"2020071612100243900_R109","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.1995.03520270033028","article-title":"Effects of estrogen or estrogen\/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) Trial.","volume":"273","year":"1995","journal-title":"JAMA"},{"key":"2020071612100243900_R110","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1532-5415.1998.tb02713.x","article-title":"Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women.","volume":"46","author":"Yaffe","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"2020071612100243900_R111","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jama.283.8.1007","article-title":"Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer\u2019s Disease Cooperative Study.","volume":"283","author":"Mulnard","year":"2000","journal-title":"JAMA"},{"key":"2020071612100243900_R112","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"2020071612100243900_R113","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/jama.1997.03550060053030","article-title":"Venous thromboembolic events associated with hormone replacement therapy.","volume":"278","author":"Grady","year":"1997","journal-title":"JAMA"},{"key":"2020071612100243900_R114","first-page":"27","article-title":"Hormone replacement therapy: where are we now?","volume":"171","author":"Stuenkel","year":"1999","journal-title":"West J Med"},{"key":"2020071612100243900_R115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1049-3867(05)80275-0","article-title":"Compliance with hormone replacement therapy: are women receiving the full impact of hormone replacement therapy preventative health benefits?","volume":"2","author":"Ravnikar","year":"1992","journal-title":"Womens Health Issues"},{"key":"2020071612100243900_R116","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","article-title":"Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.","volume":"279","author":"Walsh","year":"1998","journal-title":"JAMA"},{"key":"2020071612100243900_R117","first-page":"214","article-title":"The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.","volume":"85","author":"Walsh","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612100243900_R118","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1089\/jwh.1998.7.839","article-title":"Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene.","volume":"7","author":"Barrett-Connor","year":"1998","journal-title":"J Womens Health"},{"key":"2020071612100243900_R119","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women.","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"2020071612100243900_R119A","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","volume":"65","author":"Cauley","journal-title":"Breast Cancer Res Treat"},{"key":"2020071612100243900_R120","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/BF03343621","article-title":"Effect of SERMs on breast tissue.","volume":"22","author":"Goldstein","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"2020071612100243900_R121","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18553\/jmcp.1998.4.5.488","article-title":"Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation.","volume":"4","author":"Ettinger","year":"1998","journal-title":"J Manag Care Pharm"},{"key":"2020071612100243900_R122","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate.","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R123","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial.","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med"},{"key":"2020071612100243900_R124","first-page":"S43","article-title":"Risedronate reduces fracture risk in women with established postmenopausal osteoporosis","volume":"64","author":"Eastell","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"2020071612100243900_R125","first-page":"205","article-title":"Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures.","volume":"11","author":"Pun","year":"1989","journal-title":"Clin Ther"},{"key":"2020071612100243900_R126","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy.","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"2020071612100243900_R127","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00007632-199712151-00002","article-title":"Epidemiology of spinal osteoporosis.","volume":"22","author":"Melton III","year":"1997","journal-title":"Spine"},{"key":"2020071612100243900_R128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01622192","article-title":"Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group.","volume":"4","author":"Nevitt","year":"1994","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R129","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","article-title":"Lifetime risks of hip, Colles\u2019, or vertebral fracture and coronary heart disease among white postmenopausal women.","volume":"149","author":"Cummings","year":"1989","journal-title":"Arch Intern Med"},{"key":"2020071612100243900_R130","first-page":"S287","article-title":"Risedronate reduces hip fractures in patients with low femoral neck bone mineral density","volume":"42","author":"Miller","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2020071612100243900_R131","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1359\/jbmr.2000.15.2.183","article-title":"Bone matters: are density increases necessary to reduce fracture risk?","volume":"15","author":"Faulkner","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071612100243900_R132","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","article-title":"Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.","volume":"283","author":"Cummings","year":"2000","journal-title":"JAMA"},{"key":"2020071612100243900_R133","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(79)90640-8","article-title":"Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study.","volume":"2","author":"Hutchinson","year":"1979","journal-title":"Lancet"},{"key":"2020071612100243900_R134","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0002-9378(79)90288-6","article-title":"Effects of long-term estrogen replacement therapy. I. Metabolic effects.","volume":"133","author":"Hammond","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"2020071612100243900_R135","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM198011203032102","article-title":"Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen.","volume":"303","author":"Weiss","year":"1980","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R136","first-page":"695","article-title":"Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women.","volume":"60","author":"Williams","year":"1982","journal-title":"Obstet Gynecol"},{"key":"2020071612100243900_R137","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7326\/0003-4819-95-1-28","article-title":"Menopausal estrogen therapy and hip fractures.","volume":"95","author":"Paganini-Hill","year":"1981","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R138","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2105\/AJPH.71.2.138","article-title":"The risk of hip fracture in postmenopausal females with or without estrogen drug exposure.","volume":"71","author":"Johnson","year":"1981","journal-title":"Am J Public Health"},{"key":"2020071612100243900_R139","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.aje.a113388","article-title":"An epidemiologic study of hip fracture in postmenopausal women.","volume":"116","author":"Kreiger","year":"1982","journal-title":"Am J Epidemiol"},{"key":"2020071612100243900_R140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-102-3-319","article-title":"Long-term estrogen replacement therapy prevents bone loss and fractures.","volume":"102","author":"Ettinger","year":"1985","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R141","first-page":"457","article-title":"Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence.","volume":"67","author":"Wasnich","year":"1986","journal-title":"Obstet Gynecol"},{"key":"2020071612100243900_R142","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM198711053171901","article-title":"Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.","volume":"317","author":"Kiel","year":"1987","journal-title":"N Engl J Med"},{"key":"2020071612100243900_R143","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-113-2-95","article-title":"Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study.","volume":"113","author":"Naessen","year":"1990","journal-title":"Ann Intern Med"},{"key":"2020071612100243900_R144","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00001648-199909000-00003","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women.","volume":"10","author":"Grodstein","year":"1999","journal-title":"Epidemiology"},{"key":"2020071612100243900_R145","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/bmj.305.6862.1124","article-title":"Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.","volume":"305","author":"Kanis","year":"1992","journal-title":"BMJ"},{"key":"2020071612100243900_R146","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3109\/00016349509013475","article-title":"Risks of perimenopausal fractures\u2014a prospective population-based study.","volume":"74","author":"Tuppurainen","year":"1995","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2020071612100243900_R147","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s001980050096","article-title":"Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Swedish Hip Fracture Study Group.","volume":"8","author":"Michaelsson","year":"1998","journal-title":"Osteoporos Int"},{"key":"2020071612100243900_R148","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1136\/bmj.316.7148.1858","article-title":"Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.","volume":"316","author":"Michaelsson","year":"1998","journal-title":"BMJ"},{"key":"2020071612100243900_R149","first-page":"S43","article-title":"A five year prospective study of BMD and fracture risk in HRT treated and untreated perimenopausal women","volume":"64","author":"Beardsworth","year":"1999","journal-title":"Calcif Tissue Int"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/23\/1\/16\/8860288\/edrv0016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/23\/1\/16\/8860288\/edrv0016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T18:28:39Z","timestamp":1716402519000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/23\/1\/16\/2424106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":151,"aliases":["10.1210\/er.23.1.16"],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/edrv.23.1.0453","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,1]]}}}